Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricardo García-Muñoz

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Immunology|March 21, 2014
Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?Ricardo García-Muñoz, Luis Llorente
Human Immunology|October 4, 2016
Follicular lymphoma (FL): Immunological tolerance theory in FLRicardo García-Muñoz, Carlos Panizo
Journal of Autoimmunity|December 4, 2014
The top ten clues to understand the origin of chronic lymphocytic leukemia (CLL)Ricardo García-Muñoz, Jesús Feliu, Luis Llorente
Annals of Hematology|April 25, 2012
Immunological aspects in chronic lymphocytic leukemia (CLL) developmentRicardo García-Muñoz, Verónica Roldan Galiacho, Luis Llorente
Leukemia Research|June 16, 2009
Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?Ricardo García-Muñoz, Carlos Panizo, Maurizio Bendandi, et al.
Annals of Hematology|June 22, 2014
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximabRicardo García Muñoz, Araceli Izquierdo-Gil, Aura Muñoz, et al.
Leukemia Research Reports|March 6, 2014
Intravascular large B cell lymphomaRicardo García-Muñoz, Susana Rubio-Mediavilla, Diego Robles-de-Castro, et al.
Immunology Letters|May 26, 2004
Class I and class II MHC polymorphisms in Mexican patients with Behçet's diseaseElena Soto-Vega, Ricardo García-Muñoz, Yvonne Richaud-Patin, et al.
Immunologic Research|December 15, 2015
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activityRicardo García-Muñoz, Ascensión López-Díaz-de-Cerio, Jesus Feliu, et al.
European Journal of Haematology|May 28, 2016
First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre studyNicolás Martínez-Calle, Ana Alfonso, José Rifón, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Immunology|March 21, 2014
Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?Ricardo García-Muñoz, Luis Llorente
Human Immunology|October 4, 2016
Follicular lymphoma (FL): Immunological tolerance theory in FLRicardo García-Muñoz, Carlos Panizo
Journal of Autoimmunity|December 4, 2014
The top ten clues to understand the origin of chronic lymphocytic leukemia (CLL)Ricardo García-Muñoz, Jesús Feliu, Luis Llorente
Annals of Hematology|April 25, 2012
Immunological aspects in chronic lymphocytic leukemia (CLL) developmentRicardo García-Muñoz, Verónica Roldan Galiacho, Luis Llorente
Leukemia Research|June 16, 2009
Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?Ricardo García-Muñoz, Carlos Panizo, Maurizio Bendandi, et al.
Annals of Hematology|June 22, 2014
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximabRicardo García Muñoz, Araceli Izquierdo-Gil, Aura Muñoz, et al.
Leukemia Research Reports|March 6, 2014
Intravascular large B cell lymphomaRicardo García-Muñoz, Susana Rubio-Mediavilla, Diego Robles-de-Castro, et al.
Immunology Letters|May 26, 2004
Class I and class II MHC polymorphisms in Mexican patients with Behçet's diseaseElena Soto-Vega, Ricardo García-Muñoz, Yvonne Richaud-Patin, et al.
Immunologic Research|December 15, 2015
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activityRicardo García-Muñoz, Ascensión López-Díaz-de-Cerio, Jesus Feliu, et al.
European Journal of Haematology|May 28, 2016
First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre studyNicolás Martínez-Calle, Ana Alfonso, José Rifón, et al.
Pageof 2